Related Experiment Video
Updated: May 15, 2026
08:23
Chemiluminescence-based Assays for Detection of Nitric Oxide and its Derivatives from Autoxidation and Nitrosated Compounds
Published on: February 16, 2022
Beta blockers, nitric oxide, and cardiovascular disease
Paul M Vanhoutte1, Yuansheng Gao
1Department of Pharmacology and Pharmacy, Li Ka Shing Faculty of Medicine, University of Hong Kong, Hong Kong, China.
Current Opinion in Pharmacology
|January 9, 2013
Summary
Third-generation beta-blockers like nebivolol offer unique benefits beyond blocking beta-adrenoceptors. Their ability to enhance nitric oxide (NO) bioavailability through nitric oxide synthase (NOS) activation provides advantages in treating cardiovascular diseases.
Area of Science:
- Pharmacology
- Cardiovascular Medicine
- Biochemistry
Background:
- Third-generation beta-blockers possess properties beyond beta-adrenoceptor inhibition.
- Nitric oxide synthase (NOS) activity and nitric oxide (NO) bioavailability are crucial for cardiovascular health.
- Impaired NOS activity and reduced NO are linked to cardiovascular dysfunction.
Purpose of the Study:
- To highlight the ancillary properties of third-generation beta-blockers.
- To elucidate the mechanisms by which nebivolol and carvedilol impact nitric oxide pathways.
- To discuss the clinical implications of these NO-dependent effects in cardiovascular diseases.
Main Methods:
- Review of existing literature on third-generation beta-blockers, focusing on nebivolol and carvedilol.
- Analysis of their effects on nitric oxide synthase (NOS) activity and nitric oxide (NO) bioavailability.
- Examination of antioxidant properties and their role in preserving NOS function.
Main Results:
- Nebivolol activates nitric oxide synthase (NOS).
- Nebivolol and carvedilol reduce asymmetrical dimethylarginine (AMDA), preserving NOS activity.
- These agents enhance nitric oxide (NO) bioavailability due to antioxidant effects.
Conclusions:
- Third-generation beta-blockers demonstrate NO-dependent vasodilatory, anti-proliferative, and cardioprotective effects.
- These NO-mediated actions offer potential clinical advantages over conventional beta-blockers in hypertension and heart failure.
- Newer beta-blockers hold promise for expanded clinical applications in managing cardiovascular diseases.
Related Concept Videos
01:16Antianginal Drugs: Nitrates and β-Blockers
In cardiovascular health, antianginal drugs combat angina pectoris — a condition marked by chest pain owing to diminished blood flow to the heart.
Organic nitrates, such as nitroglycerin, play a pivotal role. Once metabolized, they liberate nitric oxide, a molecular marvel. Nitric oxide triggers guanylyl cyclase and augments cGMP production. This biochemical cascade orchestrates the relaxation of vascular smooth muscles, ushering in vasodilation and enhancing coronary blood flow. Administered...
Organic nitrates, such as nitroglycerin, play a pivotal role. Once metabolized, they liberate nitric oxide, a molecular marvel. Nitric oxide triggers guanylyl cyclase and augments cGMP production. This biochemical cascade orchestrates the relaxation of vascular smooth muscles, ushering in vasodilation and enhancing coronary blood flow. Administered...
01:22Heart Failure Drugs: β-Blockers
β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation, vasodilation, and...
01:31Adrenergic Antagonists: ɑ and β-Receptor Blockers
Third-generation β-blockers, such as labetalol and carvedilol, represent a significant advancement in managing cardiovascular conditions. Unlike conventional β-blockers, which can induce peripheral vasoconstriction, third-generation drugs block α1 adrenoceptors. This promotes vasodilation through several mechanisms, such as increased nitric oxide production, inhibition of calcium ion entry, opening of potassium ion channels, and antioxidant action. Labetalol, for instance, is clinically...
01:27Adrenergic Antagonists: Pharmacological Actions of β-Receptor Blockers
β-receptor blockers significantly impact the cardiovascular system by counteracting catecholamine-induced sympathetic responses. These medications decrease heart rate, contractility, and cardiac output, potentially leading to cardiac depression, life-threatening bradycardia, and death. Therapeutically, β-blockers function as mild antihypertensives and are utilized in treating angina pectoris and cardiac arrhythmias. However, nonselective β-blockers inhibit β2-receptors in bronchial smooth...
01:28Antihypertensive Drugs: Types of β-Blockers
β receptors are classified into three subclasses: β1, β2, and β3. β1 receptors are primarily located in the heart and kidneys. When they get activated, they increase heart rate, contractility, and renin release. This process enhances blood pressure and aids in stress management. In contrast, β2 receptors are situated mainly in the lungs, blood vessels, and skeletal muscles. Upon activation, they trigger smooth muscle relaxation, causing bronchodilation and vasodilation. This widens airways and...
01:23Antihypertensive Drugs: Vasodilators
Vasodilators, primarily affecting the smooth muscles within arterial and venous walls, are commonly used for hypertension treatment. Medications such as minoxidil and hydralazine primarily target arteries and arterioles, while sodium nitroprusside acts on arterioles and venules. Minoxidil, functioning as a prodrug, is metabolized by hepatic sulfotransferase into its active form, minoxidil sulfate, after oral administration. This metabolite binds to the sulfonylurea receptor (SUR) component of...